Sistema de Salut de Catalunya
Institut Català de la Salut
[Tarantino P] Division of New Drugs and Early Drug Development, European Institute of Oncology IRCCS, Milan, Italy. [Corti C] Division of New Drugs and Early Drug Development, European Institute of Oncology IRCCS, Milan, Italy. Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy. [Schmid P] Barts Cancer Institute, Queen Mary University of London, London, UK. [Cortes J] Oncology Department, International Breast Cancer Center (IBCC), Quiron Group, Barcelona, Spain. Medica Scientia Innovation Research (MedSIR), Barcelona, Spain. Breast Cancer Research Program, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Universidad Europea de Madrid, Faculty of Biomedical and Health Sciences, Department of Medicine, Madrid, Spain. [Mittendorf EA] Division of Breast Surgery, Department of Surgery, Brigham and Women’s Hospital, Boston, USA. Breast Oncology Program, Dana-Farber Cancer Institute, Boston, USA. [Rugo H] University of California San Francisco, UCSF Helen Diller Family Comprehensive Cancer Center Precision Medicine Cancer Building, San Francisco, USA
Vall d'Hebron Barcelona Hospital Campus
2022-07-20T10:30:46Z
2022-07-20T10:30:46Z
2022-02-18
Breast cancer; Drug development; Immunoediting
Càncer de mama; Desenvolupament de medicaments; Immunoedició
Cáncer de mama; Desarrollo de fármacos; Inmunoedición
For decades, the systemic treatment of localized triple negative breast cancer (TNBC) has exclusively relied on chemotherapy. Recent advancements, however, are rapidly reshaping the treatment algorithms for this disease. The addition of pembrolizumab to neoadjuvant chemotherapy has indeed shown to significantly improve event-free survival for stage II–III TNBC, leading to its establishment as new standard of care in this setting. This landmark advancement has however raised several important scientific questions. Indeed, we desperately need strategies to identify upfront patients deriving benefit from the addition of immunotherapy. Moreover, the best integration of pembrolizumab with further recent advancements (capecitabine, olaparib) is yet to be defined. Lastly, extensive efforts are needed to minimize the impact on patients of immune-related adverse events and financial toxicity. The next decade of clinical research will be key to overcome these challenges, and ultimately learn how to optimally integrate immunotherapy in the treatment landscape of TNBC.
Supported by an American-Italian Cancer Foundation Post-Doctoral Research Fellowship.
Article
Published version
English
Mama - Càncer - Tractament; Immunoteràpia; DISEASES::Neoplasms::Neoplasms by Site::Breast Neoplasms::Triple Negative Breast Neoplasms; Other subheadings::Other subheadings::Other subheadings::/drug therapy; ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de la mama::neoplasias de mama triple negativos; Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia
Nature Research
NPJ Breast Cancer;8
https://doi.org/10.1038/s41523-022-00386-1
Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
